Grandeur Peak Global Advisors LLC Acquires New Shares in Medpace Holdings, Inc. $MEDP

Grandeur Peak Global Advisors LLC acquired a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 148,256 shares of the company's stock, valued at approximately $1,333,000. Grandeur Peak Global Advisors LLC owned about 0.53% of Medpace at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of MEDP. Johnson Financial Group Inc. bought a new stake in Medpace in the 2nd quarter valued at about $27,000. Geneos Wealth Management Inc. grew its position in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock worth $29,000 after purchasing an additional 37 shares during the last quarter. Elyxium Wealth LLC bought a new position in Medpace in the 4th quarter worth about $30,000. Jones Financial Companies Lllp bought a new position in Medpace in the 2nd quarter worth about $30,000. Finally, Allied Private Wealth LLC acquired a new stake in shares of Medpace in the second quarter valued at approximately $31,000. Institutional investors and hedge funds own 77.98% of the company's stock.

Insider Transactions at Medpace

In other news, VP Susan E. Burwig sold 7,500 shares of the company's stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $600.00, for a total value of $4,500,000.00. Following the completion of the sale, the vice president owned 62,984 shares in the company, valued at $37,790,400. This represents a 10.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Fred B. Davenport, Jr. sold 7,283 shares of the firm's stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $606.15, for a total value of $4,414,590.45. Following the transaction, the director directly owned 3,798 shares of the company's stock, valued at $2,302,157.70. This represents a 65.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 129,963 shares of company stock valued at $79,364,624. Company insiders own 20.50% of the company's stock.

Medpace Trading Down 1.2%

Shares of NASDAQ:MEDP opened at $611.57 on Friday. The company has a 50 day moving average of $562.52 and a 200-day moving average of $493.80. The firm has a market cap of $17.07 billion, a P/E ratio of 35.85, a P/E/G ratio of 2.76 and a beta of 1.15. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business had revenue of $707.33 million during the quarter, compared to analysts' expectations of $689.51 million. During the same period last year, the firm posted $3.10 earnings per share. The business's revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Equities research analysts forecast that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Robert W. Baird boosted their price objective on Medpace from $547.00 to $624.00 and gave the stock a "neutral" rating in a research report on Friday, July 24th. TD Cowen raised their target price on Medpace from $419.00 to $492.00 and gave the company a "hold" rating in a research report on Friday, July 24th. Mizuho lifted their target price on Medpace from $586.00 to $665.00 and gave the company an "outperform" rating in a research note on Friday, July 24th. Jefferies Financial Group lowered Medpace from a "buy" rating to a "hold" rating and boosted their price target for the stock from $490.00 to $515.00 in a research report on Tuesday, July 7th. Finally, Weiss Ratings raised Medpace from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Wednesday, August 12th. Three research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $584.18.

Medpace Profile

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source